Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 8,518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Group Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Maternal Choline Supplementation and Offspring Cognition in Adolescence

NCT05859126
View directory record Official record
Conditions
Cognitive Deficit in Attention, Executive Dysfunction, Emotional Regulation
Interventions
Maternal Choline Supplementation 930 mg/d, Maternal Choline Supplementation 480 mg/d
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
13 Years to 13 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Mobile Technology and Online Tools to Improve Asthma Control in Adolescents - Usability

NCT02816216
View directory record Official record
Conditions
Asthma
Interventions
CampAir
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533
View directory record Official record
Conditions
Arthroplasty
Interventions
Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

NCT00028938
View directory record Official record
Conditions
Lung Cancer
Interventions
epoetin alfa, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

NCT06190678
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Anaheim, California • Edgewater, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02101385
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Breast Cancer
Interventions
Genomically Directed Monotherapy, Observation/Standard Therapy
Drug · Other
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Not applicable Interventional

Veterans Walk for Health Study

NCT00123435
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Hyperlipidemia, Hypertension, Obesity
Interventions
Nutritional counseling, Walking program, Simple pedometer, Enhanced pedometer
Behavioral · Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older · Male only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Artesia, California • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

NCT00474058
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

NCT00861185
View directory record Official record
Conditions
Exercise Induced Asthma
Interventions
senicapoc, Placebo
Drug
Lead sponsor
Icagen
Industry
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Huntington Beach, California • Orange, California • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 30, 2026, 6:45 AM EDT
Recruiting Not applicable Interventional

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction

NCT07507708
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Automated Insulin Delivery (AID), AIDANET + Fully Closed Loop (FCL), AIDANET + Anticipatory Closed Loop (ACL)
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Not applicable Interventional

Improving Metabolic Control in Diabetic Young Children

NCT00439985
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Video Counseling: A Randomized Control Trial

NCT04300725
View directory record Official record
Conditions
Pregnancy Related
Interventions
Video Counseling
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 30, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02484547
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Control Trial of a Virtual Patient Advocate for Preconception Care

NCT01827215
View directory record Official record
Conditions
Preconception Care
Interventions
Virtual Patient Advocate (VPA)
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid

NCT01400815
View directory record Official record
Conditions
Smoking Cessation
Interventions
X-22 Smoking Cessation Product, Active Control Cigarettes
Drug
Lead sponsor
22nd Century Limited, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Sacramento, California • Metairie, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

NCT01951625
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 30, 2026, 6:45 AM EDT
Enrolling by invitation Phase 4 Interventional

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

NCT06995352
View directory record Official record
Conditions
Moderate-to-severely Painful Ankle Surgery
Interventions
Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987
View directory record Official record
Conditions
APOL1-Mediated Kidney Disease
Interventions
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
Combination Product · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 30, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
ALXN1920, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 6:45 AM EDT